AbbVie Commits $380 Million to Build New API Facilities in North Chicago
AbbVie has announced a significant $380 million investment to construct two new active pharmaceutical ingredient (API) manufacturing facilities at its North Chicago, Illinois, campus. This move is set to bolster the company's domestic production capabilities.
New Facilities to Advance Neuroscience and Obesity Treatments
These state-of-the-art facilities are designed to integrate advanced manufacturing technologies with artificial intelligence (AI). They are specifically intended to support the production of AbbVie’s next-generation neuroscience and obesity medications.
Construction is slated to commence in spring 2026, with both facilities anticipated to be fully operational by 2029. This expansion effort also includes a substantial commitment to job creation: AbbVie plans to create 300 new jobs in North Chicago, encompassing roles for engineers, scientists, manufacturing operators, and lab technicians.
Strengthening U.S. Manufacturing and Innovation
This investment is a key component of AbbVie's broader commitment of $100 billion for U.S. research and development (R&D) and capital investments, including manufacturing, over the next decade.
Robert A. Michael, chairman and chief executive officer of AbbVie, emphasized that "strengthening U.S. manufacturing capabilities supports innovation and enhances the ability to deliver medicines to patients."
Expanding Domestic API Capacity and Global Reshoring
Over the past six months, AbbVie has actively outlined plans to bolster its API manufacturing capabilities and capacity within the U.S. This strategy includes a groundbreaking scheduled for September 2025 for a new chemical synthesis facility. This facility is specifically designed to return API production for select neuroscience, immunology, and oncology products from Europe and Asia back to the U.S.
Further demonstrating its commitment, AbbVie recently announced intentions to acquire a device manufacturing facility in Arizona and to make significant investments at its Massachusetts manufacturing facility. The company is also in discussions with several U.S. states regarding potential additional manufacturing investments, with further announcements anticipated in 2026.
AbbVie's Extensive U.S. Footprint
AbbVie maintains a substantial presence across all 50 U.S. states and Puerto Rico, employing approximately 29,000 people in the U.S. Of these, over 6,000 work at its U.S. manufacturing sites. Headquartered in Illinois, the company is a major employer in the state, with more than 11,500 people working there.